Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:ONC)

206.32 -3.09 (-1.48%)
Official Closing Price Updated: 4:15 PM EDT, Apr 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 760,520
Open 209.24
Bid (Size) 207.21 (1)
Ask (Size) 222.00 (1)
Prev. Close 209.41
Today's Range 196.45 - 211.85
52wk Range 172.67 - 287.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later. 
Via Benzinga

Performance

YTD
+12.1%
+12.1%
1 Month
-15.0%
-15.0%
3 Month
+16.0%
+16.0%
6 Month
+12.1%
+12.1%
1 Year
+12.1%
+12.1%

More News

Read More
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
From BeiGene, Ltd.
Via Business Wire
Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
Via Benzinga
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
Via Benzinga
Earnings Scheduled For March 7, 2025
Via Benzinga
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
Via Benzinga
Exposures Product Safety
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Alibaba, Super Micro Computer And XPeng Are Among Top 10 Large Cap Gainers Last Week (Feb 17-Feb 21): Are The Others In Your Portfolio?
Via Benzinga
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
From BeiGene, Ltd.
Via Business Wire
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
Via Stocktwits
Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes
Via Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
BeiGene Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga

Frequently Asked Questions

Is BeiGene, Ltd. - American Depositary Shares publicly traded?
Yes, BeiGene, Ltd. - American Depositary Shares is publicly traded.
What exchange does BeiGene, Ltd. - American Depositary Shares trade on?
BeiGene, Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BeiGene, Ltd. - American Depositary Shares?
The ticker symbol for BeiGene, Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market
What is the current price of BeiGene, Ltd. - American Depositary Shares?
The current price of BeiGene, Ltd. - American Depositary Shares is 206.32
When was BeiGene, Ltd. - American Depositary Shares last traded?
The last trade of BeiGene, Ltd. - American Depositary Shares was at 04/09/25 04:15 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.